Development and evaluation of a novel series of Nitroxoline-derived BET inhibitors with antitumor activity in renal cell carcinoma.
Chen, W., Zhang, H., Chen, Z., Jiang, H., Liao, L., Fan, S., Xing, J., Xie, Y., Chen, S., Ding, H., Chen, K., Jiang, H., Luo, C., Zheng, M., Yao, Z., Huang, Y., Zhang, Y.(2018) Oncogenesis 7: 83-83
- PubMed: 30385738 
- DOI: 10.1038/s41389-018-0093-z
- Primary Citation of Related Structures:  
5Z5T, 5Z5U, 5Z5V - PubMed Abstract: 
Small molecular inhibitors targeting BRD4 family proteins are emerging as promising therapies in many types of human malignancies. However, whether BRD4, as well as other BET family members, may serve as therapeutic targets in renal cell carcinoma (RCC) remains unknown ...